Trovagene Announces Clinical Data Presentation for Its Oncogene Mutation Monitoring Platform at the American Association for Cancer Research Annual Meeting

SAN DIEGO, April 1, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that clinical data from a study using the company's cancer monitoring platform for the detection and longitudinal monitoring of BRAF V600E mutations will be the subject of a late-breaking poster presentation at the American Association for Cancer Research Annual Meeting in San Diego, California.

Presentation Details

Title: Droplet digital PCR detection and longitudinal monitoring of BRAF mutations in cell-free urinary DNA of patients with metastatic cancers or Erdheim-Chester disease
Presenter: Filip Janku, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center
Date: Tuesday, April 8
Time: 8 a.m. to Noon PDT
Location: Hall A-E; Poster Section 39
Abstract Number: LB-170

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA and RNA in urine.  The company's technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene's diagnostic platform provides important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending applications globally.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2013 and other periodic reports filed with the Securities and Exchange Commission.


Contact




Investor Relations


Media Relations

David Moskowitz

Amy Caterina


Ian Stone

Account Director

Trovagene, Inc.


Canale Communications, Inc.

858-952-7593


619-849-5388

ir@trovagene.com


istone@canalecomm.com

Logo - http://photos.prnewswire.com/prnh/20120620/LA28014LOGO

SOURCE Trovagene, Inc.



RELATED LINKS
http://www.trovagene.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.